High-throughput screening approaches for investigating drug metabolism and pharmacokinetics

References

• ABRAHAM, M. H., 2000, High-throughput prediction of physicochemical and biochemical processes from structure, using calculated Abraham solvation descriptors. Abstracts of Papers — American Chemical Society, 220, COMP–032.
   Google Scholar
• ABRAHAM, M. H., CHADHA, H. S. and MITCHELL, R. C., 1995, Hydrogen-bonding. Part 36. Determination of blood—brain distribution using octanol—water partition coefficient. Drug Design and Discovery, 13, 123–131
   PubMedGoogle Scholar
• ABRAHAM, M. H. and LE, J., 1999, The correlation and prediction of the solubility of compounds in water using an amended solvation energy relationship. Journal of Pharmaceutical Sciences, 88, 868–880.
   PubMed Web of Science ®Google Scholar
• ANNAERT, P. P., LECLUYSE, E. L. and BROUWER, K. L. R., 2000, Modulation of P-glycoprotein (P-GP)-mediated biliary excretion in sandwich-cultured (SC) rat hepatocytes. Drug Metabolism Reviews, 32, 198.
   Google Scholar
• ARTURSSON, P. and KARLSSON, J., 1991, Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochemical and Biophysical Research Communications, 175, 880–885.
   PubMed Web of Science ®Google Scholar
• AYRTON, A. and MORGAN, P., 2001, Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica, 31, 399–427.
   PubMed Web of Science ®Google Scholar
• AYRTON, J., PLUMB, R., LEAVENS, W. J., MALLETT, D., DICKINS, M. and DEAR, G. J., 1998, Application of a generic fast gradient liquid chromatography tandem mass spectrometry method for the analysis of cytochrome P450 probe substrates. Rapid Communications in Mass Spectrometry, 12, 217–224.
   PubMed Web of Science ®Google Scholar
• BAILLIE, T. A. and PEARSON, P. G., 2000, The impact of drug metabolism in contemporary drug discovery: new opportunities and challenges for mass spectrometry. In A. J. Burlingame, S. A. Carr and M. A. Baldwin (eds), Mass Spectromeby in Biological Medicine (Totowa: Humana), pp. 481A–96.
   Google Scholar
• BAJPAI, M. and ADKISON, K. K., 2000, High-throughput screening for lead optimization: a rational approach. Current Opinions in Drug Discovery and Development, 3, 63–71.
   PubMedGoogle Scholar
• BAYLISS, M. K. and FRICK, L. W., 1999, High-throughput pharmacokinetics: cassette dosing. Current Opinions in Drug Discovery and Development, 2, 20–25.
   PubMedGoogle Scholar
• BERMAN, J., HALM, K., ADKISON, K. K. and SHAER, J. E., 1997, Simultaneous pharmacokinetic screening of a mixture of compounds in the dog using API LC/MS/MS analysis for increased throughput. Journal of Medicinal Chemistry, 40, 827–829.
   PubMed Web of Science ®Google Scholar
• BERTRAND, M., JACKSON, P. and WALTHER, B., 2000, Rapid assessment of drug metabolism in the drug discovery process. European Journal of Pharmaceutical Sciences, 11, 61–72.
   PubMed Web of Science ®Google Scholar
• BEVAN, C. D. and LLOYD, R. S., 2000, A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates. Analytical Chemistry, 72, 1781-1 787.
   Google Scholar
• BOWEN, W. P., CAREY, J. E., MIAH, A., MCMURRAY, H. F., MUNDAY, P. W., JAMES, R. S., COLEMAN, R. A. and BROWN, A. M., 2000, Measurement of cytochrome P450 gene induction in human hepatocytes using quantitative real-time reverse transcriptase-polymeraw chain reaction. Drug Metabolism and Disposition, 28, 781–788.
   PubMed Web of Science ®Google Scholar
• BOWERS, W. F., FULTON, S. and THOMPSON, J., 1984, Ultrafiltration vs equilibrium dialysis for determination of free fraction. Clinical Pharmaco kinetics, 9, 49–60.
   PubMed Web of Science ®Google Scholar
• BOX, K. J., 2000, High-throughput physicochemical profiling: a tool for lead optimization. Paper presented at the Cambridge Healthtech Institutes 2nd Annual Conference Smarter Lead Optimization, Baltimore, MD, 16–17 March.
   Google Scholar
• CALDWELL, G. W., 2000, Compound optimization in early- and late-phase drug discovery: acceptable pharmacokinetic properties utilizing combined physicochemical, in vitro and in vivo screens. Current Opinions in Drug Discovely and Development, 3, 30–41.
   PubMedGoogle Scholar
• CAMENISCH, G., ALSENZ, J, VAN DE WATERBEEMBD, H. and FOLKERS, G., 1998, Estimation of permeability by passive diffusion through Caco-2 cell monolayers using drugs' lipophilicity and molecular weight. European Journal of Pharmaceutical Sciences, 6, 313–319.
   Web of Science ®Google Scholar
• CAMENISCH, G., FOLKERS, G. and VAN DE WATERBEEMD, H., 1997, Comparison of passive drug transport through Caco-2 cells and artificial membranes. International journal of Pharmaceutics, 147, 61–70.
   Google Scholar
• CARLILE, D. J., ZOMORODI, K. and HOUSTON, J. B., 1997, Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver — studies with induced livers involving diazepam. Drug Metabolism and Disposition, 25, 903–911.
   PubMed Web of Science ®Google Scholar
• CHEE, M., YANG, R., HUBBELL, E., BEANO, A., HUANG, X. C., STERN, D., WINKLER, J., LOCKHART, D. J., MORRIS, M. S. and FODOR, S. P. A., 1996, Assessing genetic information with high-density DNA arrays. Science, 274, 610–614.
   PubMed Web of Science ®Google Scholar
• CHIKHALE, E. G., NG, K. Y., BURTON, P. S. and BORCHARDT, R. T., 1994, Hydrogen bonding potential as a determinant of the in vitro and in situ blood—brain barrier permeability of peptides. Pharmaceutical Research, 11, 412–419.
   PubMed Web of Science ®Google Scholar
• CHONG, S., DANDO, S. A. and MORRISON, R. A., 1997, Evaluation of Biocoate intestinal epithelium differentiation environment (3-day cultured Caco-2 cells) as an absorption screening model with improved productivity. Pharmaceutical Research, 14, 1835–1837.
   PubMed Web of Science ®Google Scholar
• CLARK, D. E., 1999a, Rapid calculation of polar surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. Journal of Pharmaceutical Sciences, 88, 807-81 4.
   Google Scholar
• CLARK, D. E., 1999b, Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood—brain barrier penetration. Journal of Pharmaceutical Sciences, 88, 815–821.
   PubMed Web of Science ®Google Scholar
• COMMANDEUR, J. N. M., 1999, Cytochrome P450 in drug metabolism. Chimie Nouvelle, 17, 1994–1995.
   Google Scholar
• Coous, R. G., CHEN, G. and WEIL, C., 1997, Quadrupole mass filter and quadrupole ion traps. NATO ASI Series, 504, 213–238.
   Google Scholar
• CORCORAN, O., WILSON, I. D. and NICHOLSON, J. K., 1999, Rapid multi-component detection of fluorinated drug metabolites in whole urine from a 'cassette' dose study using high resolution 19F NNIR spectroscopy. Analytical Communications, 36, 259–261.
   Web of Science ®Google Scholar
• Cox, K. A., DUNN-MEYNELL, K., KORFMACHER, W. A., BROSKE, L., NOMEIR, A. A., LIN, C.C., CAYEN, M. N. and BARR, W. H., 1999, Novel in vivo procedure for rapid pharmacokinetic screening of discovery compounds in rats. Drug Discovery Today, 4, 232–237.
   Google Scholar
• CRESPI, C. L., 1999a, Higher-throughput screening with human cytochromes P450. Current Opinions in Drug Discovery and Development, 2, 15–19.
   PubMedGoogle Scholar
• CRESPI, C. L., 1999b, Assessing the potential for drug—drug interactions in an accelerated throughput mode. Pharmaceutical Science Technology Today, 2, 119–120.
   PubMedGoogle Scholar
• CRESPI, C. L., MILLER, V. P. and PENMAN, B. W., 1997, Microtiter plate assays for inhibition of human drug metabolizing cytochromes P450. Analytical Biochemistry, 248, 1 88–190.
   Web of Science ®Google Scholar
• CRESPI, C. L., MILLER, V. P. and PENMAN, B. W., 1998, High throughput screening for inhibition of cytochrome P450 metabolism. Medicinal Chemistry Research, 8, 457–471.
   Web of Science ®Google Scholar
• CRESPI, C. L., PENMAN, B. W. and Hu, M., 1996, Development of Caco-2 cells expressing high levels of cDNA-derived cytochrome CYP3A4. Pharmaceutical Research, 13, 1635–1641.
   Web of Science ®Google Scholar
• CRIVORI, P., CRUCIANI, G., CARRUPT, P.-A. and TESTA, B., 2000, Predicting blood—brain barrier permeation from three-dimensional molecular structure. Journal of Medicinal Chemistry, 43, 2204–2216.
   Google Scholar
• CRONIN, M., 1998, Computer-aided prediction of drug toxicity in high-throughput screening. Pharmacy and Pharmacology Communications, 4, 157–163.
   Google Scholar
• CRUCIANI, G. and GusA, W., 2000, VolSurf: a new tool for the pharmacokinetic optimization of lead compounds. European Journal of Pharmaceutical Sciences, 11, S29–539.
   PubMed Web of Science ®Google Scholar
• DARVAS, F., DORMAN, G. and PAPP, A., 2000, Diversity measures for enhancing ADME admissibility of combinatorial libraries. Journal of Chemical Information and Computer Sciences, 40, 314–322.
   PubMedGoogle Scholar
• DE GROOT, M. J., ACKLAND, M. J., HORNE, V. A., ALEX, A. A. and JONES, B. C., 1999, Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6. Journal of Medicinal Chemistry, 42, 1515–1524.
   PubMed Web of Science ®Google Scholar
• DELBRESSINE, L., 2001, Organon's experience with knowledge management in preclinical development. Paper presented at the DMDG 1 Day Meeting, Informatics and In Silko Modelling in DM/PK, Ware, 15 February.
   Google Scholar
• DELIE, F. and Rumas, W., 1997, A human colonic cell line sharing similarities with enterocytes as a model to examine oral absorption: advantages and limitations of the Caco-2 model. Critical Review of Therapeutk Drug Carrier Systems, 14, 221–286.
   PubMed Web of Science ®Google Scholar
• DIKE, L. E., GUARINO, R. and TIMMINS, M., 2000, Development of a high throughput, fluorescent assay system to determine relative rates of metabolism. Drug Metabolism Reviews, 32, 183.
   Google Scholar
• DOPPENSCHMITP, S., LANGGUTH, P., REGARDH, C. G., ANDERSSON, T. B., HILGENDORF, C. and SPAHN-LANGGum, H., 1999, Characterisation of binding properties to human P-glycoprotein: development of a [3H]veraparnil radioligand-binding assay. Journal of Pharmacology and Experimental Therapeutics, 288, 348–357.
   Google Scholar
• EARLL, M., 1999, A guide to log P and pKa measurements and their use [http://www.raell.demon.co.uk/ chem/logp/logpka.html].
   Google Scholar
• EASTERLING, M. L. and AMSTER, I. J., 1997, Fourier transform mass spectrometry. NATO ASI Series, 504, 287–314.
   Google Scholar
• EDDERSHAW, P. J., BERESFORD, A. P. and BAYLISS, M. K., 2000, ADME/PK as part of a rational approach to drug discovery. Drug Discoveiy Today, 5, 409–414.
   PubMed Web of Science ®Google Scholar
• EGAN, W. J., MERZ, K. M. and BALDWIN, J. J., 2000, Prediction of drug absorption using multivariate statistics. Journal of Medicinal Chemistry, 43, 3867–3877.
   PubMed Web of Science ®Google Scholar
• EKINS, S., MURRAY, G. I., BURKE, M. D., WILLIAMS, J. A., MARCHANT, N. C. and HAWKSWORTH, G. M., 1995, Quantitative differences in phase I and II metabolism between rat precision-cut liver slices and isolated hepatocytes. Drug Metabolism and Disposition, 23, 1274-1 279.
   PubMed Web of Science ®Google Scholar
• EPPS, D. E., RAKE, T. J. and KEZDY, F. J., 1995, A general, wide-range spectrofluorometric method for measuring the site-specific affinities of drugs toward human serum albumin. Analytical Biochemistry, 227, 342–350.
   PubMed Web of Science ®Google Scholar
• ERHARDT, P. W., 1998, Drug metabolism data: past and present status. Medicinal Chemistry Research, 8, 400–421.
   Web of Science ®Google Scholar
• FRICK, L. W., ADKISON, K. K., WELLS-KNECHT, K. J., WOOLAND, P. and HIGTON, D. M., 1998, Cassette dosing: rapid in vivo assessment of pharmacokinetics. Pharmaceutical Science and Technology Today, 1, 12–18.
   Google Scholar
• GEORGE, A., 1999, The design and molecular modeling of CNS drugs. Current Opinions in Drug Discovery and Development, 2, 286–292.
   PubMedGoogle Scholar
• GHOSAL, A., HAPANGAMA, N., YUAN, Y., FARREAU, L. V., PALAMANDER, J. R., PATRICK, J. E., CAYEN, M. N. and ZBAIDA, S., 2000, Microtiter plate-based assay for rapid determination of enzyme activities of 13 P450 supersomes and human liver microsomes. Drug Metabolism Reviews, 32, 188.
   Google Scholar
• GIDDINGS, S. J., CLARKE, S. E. and GIBSON, G. G., 1997, CYP4A1 gene transfection studies and the peroxisome proliferator-activated receptor: development of a high-throughput assay to detect peroxisome proliferators. European Journal of Drug Metabolism and Pharmacokinetics, 22, 315–319.
   PubMed Web of Science ®Google Scholar
• GILBERT, J. D., OKut, T. V. and McLouumAK, D. A., 1996, High-performance liquid chromatography with atmospheric pressure ionization tandem mass spectrometry as a tool in quantitative bioanalytical chemistry. American Chemical Society Symposium Series, 619, 330–350.
   Google Scholar
• GONZALEZ, F. J., CRESPI, C. L., CZERWINSKI, M. and GELBOIN, H. V., 1992, Analysis of human cytochrome P450 catalytic activities and expression. Tohoku Journal of Experimental Medicine, 168, 67–72.
   PubMed Web of Science ®Google Scholar
• GRASS, G. M., 1997, Simulation models to predict oral drug absorption from in vitro data. Advanced Drug Delivery Reviews, 23, 199–219.
   Web of Science ®Google Scholar
• GU, C., Nutouc, D., LAI, J., Xu, X. and VAN BREEMEN, R. B., 1999, Assays of ligand-human serum albumin binding using pulsed ultrafiltration and liquid chromatography mass spectrometry. Combinatorial Chemistry and High Throughput Screening, 2, 353–359.
   PubMed Web of Science ®Google Scholar
• HALLIDAY, R. C., JoKEs, B. C., PARK, B. K. and SMITH, D. A., 1997, Synthetic strategies to lower affinity for CYP2D6. European Journal of Drug Metabolism and Pharmacokinetics, 22, 291–294.
   PubMed Web of Science ®Google Scholar
• HAWKINS, D. R., 1999, Use and value of metabolism databases. Drug Discovery Today, 4, 466–471.
   PubMed Web of Science ®Google Scholar
• HENION, J., BREWER, E. and RULE, G., 1998, Sample preparation for LC/MS/MS: analyzing biological and environmental samples. Analytical Chemistry, 70, 650–656.
   PubMed Web of Science ®Google Scholar
• HERMAN, R. A. and VENG-PEDERSON, P., 1994, Quantitative structure—pharmacokinetic relationships for systemic drug distribution kinetics not confined to a congeneric series. Journal of Pharmaceutical Sciences, 83, 423–428.
   Google Scholar
• HERRERA, A. M., SCOTT, D. O. and LUNTE, C. E., 1990, Microdialysis sampling for determination of plasma protein binding of drugs. Pharmaceutical Research, 7, 1077–1081.
   PubMed Web of Science ®Google Scholar
• HOLLENBERG, P. F. and SCARPELLI, D. G., 1988, Uptake of N-nitrosobis(2-oxopropyl)amine by isolated rat and hamster hepatocytes: species differences and evidence for an active carrier-mediated transport process. Carcinogenesis, 9, 1763–1772.
   Google Scholar
• HOP, C. E., WANG, Z., CHEN, Q. and KWEI, G., 1998, Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. Journal of Pharmaceutical Sciences, 87, 901–903.
   PubMed Web of Science ®Google Scholar
• HUUSKONEN, J., RANTAXEN, J. and LIVINGSTONE, D., 2000, Prediction of aqueous solubility for a diverse set of organic compounds based on atom-type electrotopological state indices. European Journal of Medicinal Chemistry, 35, 1081–1088.
   PubMed Web of Science ®Google Scholar
• HYDE, R. M. and HERSEY, A., 1996, Screening, and rational drug design — competitive or complementary? In M. G. Ford, R. Greenwood, G. T. Brooks and R. Frankel (eds), Bioactive Compound Design: Possibilities for Industrial Use (Oxford: Bios), pp. 37–45.
   Google Scholar
• IRVINE, J. D., TAKAHASHI, L., LOCKHART, K., CHEONG, J., TOLAN, J. W., SELICK, H. E. and GROVE, J. R., 1999, MDCK (Madin—Darby canine kidney) cells: a tool for membrane permeability screening. Journal of Pharmaceutical Sciences, 88, 28–33.
   PubMed Web of Science ®Google Scholar
• IWATSUBO, T., HIROTA, N., O01E, T., SUZUKI, H., SHIMADA, N., CHIBA, K., ISHIZAKI, T., GREEN, C. E., TYSON, C. A. and SUGIYAMA, Y., 1997, Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacology and Therapeutics, 73, 147–172.
   Google Scholar
• JOHNSON, D. E. and WOLFGANG, G. H. I., 2000, Predicting human safety: screening and computational approaches. Drug Discovery Today, 5, 445–454.
   PubMed Web of Science ®Google Scholar
• JOHNSON, D. L., KELLY, K. G., GAO, F., MEYER, R. D., MORRIS, J. C., WEST, M. and EKINS, S. E., 2000, Single point screening for high throughput methods to predict drug—drug interaction potential. Drug Metabolism Reviews, 32, 185.
   Google Scholar
• KANSY, M., SENNER, F. and GUBERNATOR, K., 1998, Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. Journal of Medicinal Chemistry, 41, 1007-1 O10.
   PubMed Web of Science ®Google Scholar
• KASUHARA, H. and SUGIYAMI, Y., 2001, Efflux transport systems for drugs at the blood—brain barrier and blood—cerebrospinal fluid barrier (Part 1). Drug Discovery Today, 6, 150–156.
   PubMed Web of Science ®Google Scholar
• KELDER, J., GROOTENHUIS, D. J., BAYADA, D. M., DELBRESSINE, P. C. and PLOEMEN, J.-P., 1999, Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharmaceutical Research, 16, 1514–1519.
   Google Scholar
• KENNEDY, T., 1997, Managing the drug discovery/development interface. Drug Discovery Today, 2, 436–444.
   Web of Science ®Google Scholar
• KIM, R. B., 2000, Transporters and drug disposition. Current Opinions in Drug Discovery and Development, 3, 94–101.
   PubMedGoogle Scholar
• KIM, R. B., FROMM, M. F., WANDEL, C., LEAKE, B., WOOD, A. J. J., RODEN, D. M. and WILKINSON, G. R., 1998, The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. Journal of Clinical Investigation, 101, 289–294.
   Google Scholar
• KLOPMAN, G., Tu, M. and FAN, B. T., 1999, META. Part 4. Prediction of the metabolism of polycyclic aromatic hydrocarbons. Theoretical Chemistry Accounts, 102, 33–38.
   Web of Science ®Google Scholar
• KOBAYASHI, K., SOGAME, Y., HARA, H. and HAYASHI, K., 1990, Mechanism of glutathione S-conjugate transport in canalicular and basolateral rat liver plasma membranes. Journal of Biological Chemistry, 265, 7737–7741.
   PubMed Web of Science ®Google Scholar
• KOEHLER, R. A., DIXON, S. L. and VILLAR, H. O., 1999, LASSOO: a generalised directed diversity approach to the design and enrichment of chemical libraries. Journal of Medicinal Chemistry, 42, 4695–4704.
   PubMed Web of Science ®Google Scholar
• KORFMACHER, W. A., Cox, K. A., BRYANT, M. S., VEALS, J., NG, K., WATKINS, R. and LIN, C.-C., 1997, HPLC-API/MS/MS: a powerful tool for integrating drug metabolism into the drug discovery process. Drug Discovery Today, 2, 532–537.
   Google Scholar
• KORFMACHER, W. A., PALMER, C. A., NARDO, C., DUNN-MEYNELL, K., GROTZ, D., Cox, K., LIN, C.C., ELICONE, C. and DUCHOSLAV, E., 1999, Development of an automated mass spectrometry system for the quantitative analysis of liver microsomal incubation samples: a tool for rapid screening of new compounds for metabolic stability. Rapid Communications in Mass Spectrometry, 13, 901–907.
   Google Scholar
• LEAHY, D. E., ARUNDEL, P. A., BLAKEY, G. E. and ROWLAND, M., 1996, Physiologic based pharmacokinetic modelling and QSAR. In M. G. Ford, R. Greenwood, G. T. Brooks and R. Frankel (eds), Bioactive Compound Design: Possibilities for Industrial Use (Oxford: Bios), pp. 147–151.
   Google Scholar
• LEE, C. P., DE VRUEH, R. L. A. and SMITH, P. L., 1997, Selection of development candidates based on in vitro permeability measurements. Advances in Drug Delivery Reviews, 23, 47–62.
   Google Scholar
• LEHMANN, J. M., McKEE, D. D., WATSON, M. A., WILLSON, T. M., MOORE, J. T. and KLIEWER, S. A., 1998, The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. Journal of Clinical Investigation, 102, 1016-1 023.
   Google Scholar
• LEWIS, D. F., DICKINS, M., WEAVER, R. J., EDDERSHAW, P. G., GOLDFARB, P. S. and TARBIT, M. H., 1998, Molecular modelling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: rationalization of substrate specificity and site-directed mutagenesis experiments in the CYP2C subfamily. Xenobiotica, 28, 235–268.
   PubMed Web of Science ®Google Scholar
• LEWIS, D. F., EDDERSHAW, P. J., GOLDFARB, P. S. and TARBIT, M. H., 1997, Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific CYP2D6 substrate metabolism. Xenobiotica, 27, 319–339.
   PubMed Web of Science ®Google Scholar
• LEWIS, D. F. V., IOANNIDES, C. and PARKE, D. V., 1990, A prospective toxicity evaluation (COMPACT) on 40 chemicals currently being tested by the National Toxicology Program. Mutagenesis, 5, 433–435.
   Google Scholar
• LI, A., 1999, Higher throughput metabolism assays using human hepatocytes. Paper presented at the AAPS Annual Meeting, New Orleans, LA, Symposium Proceedings.
   Google Scholar
• LI, A. P., Lu, C., BRENT, J. A., PHAM, C., FACKETT, A., RUEGG, C. E. and SILBER, P. M., 1999, Cryopreserved human hepatocytes: characterisation of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug—drug interaction potential. Chemko-Biological Interactions, 121, 17–35.
   PubMed Web of Science ®Google Scholar
• LI, A. P., MAUREL, P., GOMEZ-LECHON, M. J., CHENG, L. C. and JuRimA-RomET, M., 1997, Preclinical evaluation of drug—drug interaction potential: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction. Chemico-Biological Interactions, 107, 5–16.
   Google Scholar
• LIN, J. H. and Lu, A. Y., 1998, Inhibition and induction of cytochrome P450 and the clinical implications. Clinical Pharmacokinetics, 35, 361–390.
   PubMed Web of Science ®Google Scholar
• LIPINSKI, C. A., LOMBARDO, F., DOMINY, B. W. and FEENEY, P. J., 1997, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 23, 3–25.
   Web of Science ®Google Scholar
• MADAN, A., DEHAAN, R., MUDRA, D., CARROLL, K., LECLUYSE, E. and PARKINSON, A., 1999, Effect of cryopreservation on cytochrome P-450 enzyme induction in cultured rat hepatocytes. Drug Metabolism and Disposition, 27, 327–335.
   PubMed Web of Science ®Google Scholar
• MARCHANT, C. A. and COMBES, R. D., 1996, Artificial intelligence: the use of computer models in the prediction of metabolism and toxicity. In M. G. Ford, R. Greenwood, G. T. Brooks and R. Frankel (eds), Bioactive Compound Design: Possibilities for Industrial Use (Oxford: Bios), pp. 153–162.
   Google Scholar
• MCCARTHY, S., OSBOURNE, S. and KUHFELD, M., 1996, Automated permeability analysis of mixtures across Caco-2 cell monolayers. Pharmacology Research, 13, S242.
   Google Scholar
• MICHNE, W. F., 1996, Hit-to-lead chemistry: a key element in new lead generation. Pharmaceutical News, 3, 19–21.
   Google Scholar
• MOODY, G. C., GRIN, S. J., MATHER, A. N., MCGINNITY, D. F. and RILEY, R. J., 1999, Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential. Xenobiotica, 9, 53–75.
   Web of Science ®Google Scholar
• MOORE, J. T. and KLIEWER, S. A., 2000, Use of the nuclear receptor PXR to predict drug interactions. Toxicology, 153, 1–10.
   PubMed Web of Science ®Google Scholar
• MULLINS, M. E., HOROWITZ, B. Z., LINDEN, D. H., SMITH, G. W., NORTON, R. L. and STUMP, J., 1998, Life-threatening interaction of mibefradil and beta blockers with dihydropyridine calcium channel blockers. Journal of American Medical Association, 280, 157–158.
   PubMed Web of Science ®Google Scholar
• NTAVIA, M. A. and CHATURVEDI, P. R., 1996, Design principles for orally bioavailable drugs. Drug Discovery Today, 1, 179–189.
   Web of Science ®Google Scholar
• NESTEROV, I. A., ÄARONS, L. and ROWLAND, M., 1997, Physiologically based pharmacokinetic modelling of a homologous series of barbiturates in the rat: a sensitivity analysis. Journal of Pharmacokinetics and Biopharmacy, 25, 413–447.
   Google Scholar
• NIINUMA, K., KATO, Y., SUZUKI, H., TYSON, C. A., WEIZER, V., DABBS, J. E., FROEHLICH, R., GREEN, C. E. and SUGIYAMA, Y., 1999, Primary active transport of organic anions on bile canalicular membrane in humans. American Journal of Physiology, 276, G1153—G1164.
   Google Scholar
• NORDYKE, A., BESTOR, J. K., YERINO, P. P., HANSEN, D. K., BEHLOW, H. W., MILLER, T. D. and THOMPSON, T. N., 2000, Validation of an improved automated incubation procedure used to screen metabolic stability of multiple compounds in parallel. Drug Metabolism Reviews, 32, 183.
   Google Scholar
• NORINDER, U., OSTERBERG, T. and ÄRTURSSON, P., 1999, Theoretical calculation and prediction of intestinal absorption of drugs in humans using MolSurf parametrization and PLS statistics. European Journal of Pharmaceutical Sciences, 8, 49–56.
   Google Scholar
• NORINDER, U., SJOBERG, P. and OSTERBERG, T., 1998, Theoretical calculation and prediction of brain—blood partitioning of organic solutes using MolSurf parametrization and PLS statistics. Journal of Pharmaceutical Sciences, 87, 952–959.
   PubMed Web of Science ®Google Scholar
• OBACH, R. S., BAXTER, J. G., LISTON, T. E., SILBER, B. M., JONES, B. C., MACINTYRE, F., RANCE, D. J. and WASTALL, P., 1997, The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. Journal of Pharmacology and Experimental Therapeutics, 283, 46–58.
   PubMed Web of Science ®Google Scholar
• OGG, M. S., WILLIAMS, J. M., TARBIT, M., GOLDFARB, P. S., GRAY, T. J. B. and GIBSON, G. G., 1999, A reporter gene assay to assess the molecular mechanisms of xenobiotic- dependent induction of the human CYP3A4 gene in vitro. Xenobiotica, 29, 269–279.
   Google Scholar
• OUATT, T. V., McLouGHLIN, D. A. and GILBERT, J. D., 1997, The simultaneous determination of mixtures of drug candidates by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry as an in vivo drug screening procedure. Rapid Communications in Mass Spectrometry, 11, 17–23.
   PubMed Web of Science ®Google Scholar
• PACICI, G. M. and VIANI, A., 1992, Methods for determining plasma and tissue binding of drugs. Clinical Pharmacokinetics, 23, 449–468.
   PubMed Web of Science ®Google Scholar
• PAGE, M. J., AMESS, B., ROHL, C., STUBBERELD, C. and PAREKH, R., 1999, Proteomics: a major new technology for the drug discovery process. Drug Discovery Today, 4, 55–62.
   PubMed Web of Science ®Google Scholar
• PAGLIARI, A., REIST, M., GEINOZ, S., CARRUPT, P.-A. and TESTA, B., 1999, Evaluation and prediction of drug permeation. Journal of Pharmacy and Pharmacology, 51, 1339–1357.
   Google Scholar
• PALM, K., STENBERG, P., LUTHMAN, K. and ARTLIRSSON, P., 1997, Polar surface properties predict the intestinal absorption of drugs in humans. Pharmaceutical Research, 14, 568–571.
   PubMed Web of Science ®Google Scholar
• PAN, J., XIANG, Q. and BALL, S., 2000, Use of a novel real-time quantitative reverse transcription-polymerase chain reaction method to study the effects of cytokines on cytochrome P450 mRNA expression in mouse liver. Drug Metabolism and Disposition, 28, 709–713.
   PubMed Web of Science ®Google Scholar
• PARDRIDGE, W. M., 1998, CNS drug design based in principles of blood—brain barrier transport. Journal of Neurochemistry, 70, 1781–1792.
   PubMed Web of Science ®Google Scholar
• PARIKH, H. H., MCELWAIN, K., BALUASUBRAMANIAN, V., LEUNG, W., WONG, D., MORRIS, M. E. and RAMANATHAN, M., 2000, A rapid spectrofluorometric technique for determining drug—serum protein binding suitable for high-throughput screening. Pharmaceutical Research, 17, 632–637.
   PubMed Web of Science ®Google Scholar
• PLATTS, J. A., 2000, Rapid automated prediction of Abraham LSER descriptors. Abstracts of Papers — American Chemistry Society, 220, COMP–135.
   Google Scholar
• PIDGEON, C., ONG, S., Liu, H., Qui, X., PIDGEON, M., DANTZIG, A. H., MUNROE, J., HORNBACK, W. J., KASHER, J. S., GLUNZ, L. and SZCZERBA, T., 1995, IANI chromatography: an in vitro screen for predicting drug membrane permeability. Journal of Medicinal Chemistry, 38, 590–594.
   PubMed Web of Science ®Google Scholar
• PRENTIS, R. A., Lis, Y. and WALKER, S. R., 1988, Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). British Journal of Clinical Pharmacology, 25, 387–396.
   PubMed Web of Science ®Google Scholar
• RICHARD, A. M., 1998, Commercial toxicology prediction systems: a regulatory perspective. Toxicology Letters, 102/103, 607–612.
   Google Scholar
• ROBERTSON, D. G. and BULERA, S. J., 2000, High-throughput toxicology: practical considerations. Current Opinions in Drug Discovery and Development, 3, 42–47.
   PubMedGoogle Scholar
• RODRIGUES, A. D., SURBER, B. W., YAO, Y., WONG, S. L. and ROBERTS, E. M., 1997, [0-ethyl 14C]phenacetin O-deethylase activity in human liver microsomes. Drug Metabolism and Disposition, 25, 1097–1100.
   PubMed Web of Science ®Google Scholar
• ROSENBERG, S. H., SPINA, K. P., WOODS, K. W., POLAKOWSKI, J., MARTIN, D. L., YAO, Z., STEIN, H. H., COHEN, J. and BARLOW, J. L., 1993, Studies directed toward the design of orally active renin inhibitors. 1. Some factors influencing the absorption of small peptides. Journal of Medicinal Chemistry, 36, 449–459.
   PubMed Web of Science ®Google Scholar
• RUELLE, P. and KESSELRING, V. W., 1998, The hydrophobic effect. 2. Relative importance of the hydrophobic effect on the solubility of hydrophobes and pharmaceuticals in H-bonded solvents. Journal of Pharmaceutical Sciences, 87, 998–1014.
   PubMed Web of Science ®Google Scholar
• RYU, D.-Y., LEVI, P. E., FERNANDEZ-SALGUERO, P., GONZALEZ, F. J. and HODGSON, E., 1996, Piperonyl butoxide and acenaphthylene induce cytochrome P450 1A2 and 1B1 mRNA in aromatic hydrocarbon response receptor knock-out mouse liver. Molecular Pharmacology, 50, 443–446.
   PubMed Web of Science ®Google Scholar
• SADOWSKI, J. and KUBINYI, H., 1998, A scoring scheme for discriminating between drugs and non-drugs. Journal of Medicinal Chemistry, 41, 3325–3329.
   PubMed Web of Science ®Google Scholar
• SAWAI, Y., YAMAOKA., K. and NAKAGAWA, T., 1998, Effect of coadministered uridine on intestinal first-pass metabolism of 5'-deoxy-5-fluorouridine in conscious rats — an evaluation by method of portal—systemic concentration difference. Pharmaceutical Research, 15, 1007–1 011.
   Google Scholar
• SEELIG, A., 1998, A general pattern for substrate recognition by P-glycoprotein. European Journal of Biochemistry, 251, 252–261.
   PubMedGoogle Scholar
• SEGALL, M. D., PAYNE, M. C., ELLIS, S. W., TUCKER, G. T. and BOYES, R. N., 1997, Ab initio molecular modeling in the study of drug metabolism. European Journal of Drug Metabolism and Pharmacokinetics, 22, 283–289.
   PubMed Web of Science ®Google Scholar
• SHAH, A. V., WALTERS, W. P. and MURCKO, M. A., 1998, Can we learn to distinguish between 'drug-like' and `nondrug-like' molecules? Journal of Medicinal Chemistry, 41, 3314–3324.
   Google Scholar
• SHAROM, F. J., Yu, X., Lu, P., Liu, R., CHU, J. W. K., SZABO, K., MULLER, M., HOSE, C. D., MONKS, A., VARADI, A., SEPRODI, J. and SARKADI, B., 1999, Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted systems, and intact cells. Biochemical Pharmacology, 58, 571–586.
   Google Scholar
• SHITARA, Y., SUZUKI, H., KATO, Y., SUGIYAMA, D., TOKUI, T, ABE, T., Pron, T. and SUGIYAMA, Y., 2000, Comparative effects of inhibitors on rat OATP1- and OATP2-mediated transport investigation of specific inhibitors. Drug Metabolism Reviews, 32, 194.
   Google Scholar
• SILVA, J. M., MORIN, P. E., DAY, S. H., KENNEDY, B. P., PAYETTE, P, RUSHMORE, T., YERGEY, J. A. and NICOLL-GRITH, D. A., 1998, Refinement of an in vitro cell model for cytochrome P450 induction. Drug Metabolism and Disposition, 26, 490–496.
   Google Scholar
• SIMPSON, H., BARTHEMY, A., BUHRMAN, D., BURTON, R., NEWTON, J., KEALY, M. and Wu, D., 1998, High throughput liquid chromatography/mass spectrometry bioanalysis using 96-well disk solid phase extraction plates for the sample preparation. Rapid Communications in Mass Spectrometry, 12, 75–82.
   PubMed Web of Science ®Google Scholar
• SINKO, P. J., 1999, Drug selection in early drug development: screening for acceptable pharmacokinetic properties using combined in vitro and computational approaches. Current Opinions in Drug Discovery and Development, 2, 42–48.
   PubMedGoogle Scholar
• SINKO, P. J., LEESMAN, G. D., WAuLawsxl, A. P., Yu, H. and Kou, J. H., 1996, Analysis of intestinal perfusion data for highly permeable drugs using a numerical aqueous resistance-non-linear regression method. Pharmaceutical Research, 13, 570–576.
   PubMed Web of Science ®Google Scholar
• SMITH, D. A., 1998, High throughput drug metabolism. Biomedical Health Research, 25, 137–143.
   Google Scholar
• STEIN, W. D. and HOSHEN, M. B., 1996, The role of ligand-binding proteins in increasing the transcellular flux of metabolites, in particular that of calcium, bilirubin, and fatty acids. Comparative Biochemistry and Physiology, Part B: Biochemistry and Molecular Biology, 115, 307–312.
   Web of Science ®Google Scholar
• STEWART, B. H., CHAN, O. H., JEZYK, N. and FLEISHER, D., 1997, Discrimination between drug candidates using models of intestinal absorption. Advances in Drug Delivery Reviews, 23, 27–45.
   Web of Science ®Google Scholar
• SUGIYAMA, Y. and Suzuxi, H., 2000, Role of MRP2 and MRP3 in the xenobiotics detoxification in the liver and small intestine. Drug Metabolism Reviews, 32, 137.
   PubMedGoogle Scholar
• SURRY, D. D., MCALLISTER, G., MENESES-LORENTE, G. and EVANS, D. C., 1999, High throughput ribonuclease protection assay for the determination of CYP3A mRNA induction in cultured rat hepatocytes. Xenobiotica, 29, 827–838.
   Google Scholar
• SWANN, P. W. and TUKKER, J. J., 1997, Molecular determinants of recognition for the intestinal peptide carrier. Journal of Pharmaceutical Sciences, 86, 596–602.
   PubMed Web of Science ®Google Scholar
• SZLARZ, G. D. and HALPERT, J. R., 1997, Molecular modeling of cytochrome P450 3A4. Journal of Computer Aided Molecular Design, 11, 265–272.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI, L., 2000, Rapid permeability screening using MDCK cells in a novel device. Paper presented at the Cambridge Healthtech Institutes 2nd Annual Conference: Smarter Lead Optimization, Baltimore, MD, 16–17 March.
   Google Scholar
• TARBIT, M. H. and BERMAN, J., 1998, High throughput approaches for evaluating absorption, distribution, metabolism and excretion properties of lead compounds. Current Opinion in Chemical Biology, 2, 411–416.
   PubMed Web of Science ®Google Scholar
• TASKINEN, J., 2000, Prediction of aqueous solubility in drug design. Current Opinions in Drug Discovery and Development, 3, 102–107.
   PubMedGoogle Scholar
• TODD, M. D. and ULRICH, R. G., 1999, Emerging technologies for accelerated toxicity evaluation of potential drug candidates. Current Opinions in Drug Discovery Development, 2, 58–68.
   PubMedGoogle Scholar
• TOMINAGA, Y., 1999, Comparative study of class data analysis with PCA-LDA, SIMCA, PLS, ANNs and k-NN. Chemometrics and Intelligent Laboratory Systems, 49, 105–115.
   Web of Science ®Google Scholar
• TROPSH A., 2000, Recent trends in computer-aided drug discovery. Current Opinions in Drug Discovery and Development, 3, 310–313.
   PubMedGoogle Scholar
• VAN BREEMEN, R. B., Nixouc, D. and BOLTON, J. L., 1998, Metabolic screening using on-line ultrafiltration mass spectrometry. Drug Metabolism and Disposition, 26, 85–90.
   PubMed Web of Science ®Google Scholar
• VAN DE WATERBEEMBD, H., CAMENISCH, G., FOLKERS, G. and RAEVSKY, O. A., 1996, Estimation of Caco-2 cell permeability using calculated molecular descriptors. Quantitative Structure Activity Relationships, 15, 480–490.
   Google Scholar
• WALLACE, R. W., 1997, High-throughput screening. HTS and gene chip technology. Drug Discovery Today, 2, 557–558.
   Web of Science ®Google Scholar
• WALLACE, R. W., 1999, Pharmacogenomics: the next logical step. Drug Discovery Today, 4, 105–107.
   PubMed Web of Science ®Google Scholar
• WALTERS, W. P. STAHL, M. T. and MURCKO, M. A., 1998, Virtual screening — an overview. Drug Discovery Today, 3, 160–178.
   Web of Science ®Google Scholar
• WATT, A. P., MORRISON, D. and EVANS, D. C., 2000, Approaches to higher throughput pharmacokinetics (HTPK) in drug discovery. Drug Discovery Today, 5, 17–24.
   PubMed Web of Science ®Google Scholar
• WESSEL, M. D., Juts, P. C., TOLAN, J. W. and MusKAL, S. M., 1998, Prediction of human intestinal absorption of drug compounds from molecular structure. Journal of Chemical Information and Computer Sciences, 38, 726–735.
   PubMedGoogle Scholar
• WINIWARTER, S., BONHAM, N. M., Ax, F., HALLBERG, A., LENNERNAS, H. and KARLEN, A., 1998, Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. Journal of Medicinal Chemistry, 41, 4939–4949.
   PubMed Web of Science ®Google Scholar
• WOLF, R. C. and HENDERSON, C. J., 1998, Use of transgenic animals in understanding molecular mechanisms of toxicity. Journal of Pharmacy and Pharmacology, 50, 567–574.
   PubMed Web of Science ®Google Scholar
• WORBOYS, P. D. and CARLILE, D. J., 2001, Implications and consequences of enzyme induction on preclinical and clinical drug development. 31, 469–486.
   Google Scholar
• WORTELBOER, H. M., DEKRUIF, C. A., VAN TEASEL, A. A. J., FALKE. H. E. and NOORDHOEK, J., 1991, Comparison of cytochrome P450 isozyme profiles in rat liver and hepatocyte cultures. The effects on apoproteins and biotransformation activities. Biochemical Pharmacology, 42, 381–390.
   Google Scholar
• WRING, S. A., HARMAN, K. A., BRUNER, J., Pow, J. W. and SERABJIT-SINGH, C., 2000, Automated plasma protein binding screen: rapid, robust and timely for drug discovery. Drug Metabolism Reviews, 32, 179.
   Google Scholar
• WYNALDA, M. A. and WIENKERS, L. C., 1997, Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P-450 enzymes using a simple in vitro inhibition screen. Drug Metabolism and Disposition, 25, 1211–1214.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI, M., SUZUKI, H. and SUGIYAMA, Y., 1996, Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharmaceutical Research, 13, 497–513.
   PubMed Web of Science ®Google Scholar
• YANG, R. S. H., THOMAS, R. S., GUSTAFSON, D. L., CAMPAIN, J., BENJAMIN, S. A., VERHAAR, H. J. M. and MUMTAZ, M. M., 1998, Approaches to developing alternative and predictive toxicology based on PBPK/PD and QSAR modeling. Environmental Health Perspectives, 106, 1385–1393.
   Google Scholar
• YIN, H., Li, S., RactiA, J., OLEJNIK, N., SATOH, H. and MOORE, D., 2000, Automated high throughput human CYP isoforrn activity assay using SPE-LC/MS method: application in CYP inhibition evaluation. Xenobiotica, 30, 141–154.
   PubMed Web of Science ®Google Scholar
• ZHANG, J. H., CHUNG, T. D. Y. and OLDENBERG, K. R., 2000, Confirmation of primary active substances from high throughput screening of chemical and biological populations: a statistical approach and practical considerations. Journal of Combinatorial Chemistry, 2, 258–265.
   Google Scholar